Navigation Links
Ellex 2RT Study Demonstrates Clinical Efficacy in Treatment of Diabetic Macular Edema
Date:11/10/2007

ctive RPE treatment in diabetic maculopathy and macular edema. The duration of the study is 12 months with patient follow up at three, six and twelve months post-op. All patients received treatments with Ellex 2RT prototype lasers that were developed specifically for the Ellex 2RT research program by Ellex's advanced research team in Adelaide, Australia. Ellex has international patents pending for the technology and the method.

At three months the majority of patients experienced improvement in visual acuity and central macular thickness (CMT) as measured by optical coherence tomography. Central macular thickness decreased in 55% of eyes and remained stable in 24%. An increase in central macular thickness was observed in only 20% of eyes. In addition, micro-perimetry confirmed that there was no evidence of laser damage to the photoreceptor cells.

ABOUT ELLEX 2RT RESEARCH

Ellex 2RT research is funded in part by an A$1.9 million, two-year Commercial Ready Grant awarded to Ellex by the Australian Government to support the development of a new and innovative laser therapy for the treatment of AMD and other retinal diseases. The grant was applied for in order to expand laboratory and clinical research in Australia based on proof- of-principle laboratory work conducted at St. Thomas' Hospital in London under the direction of Professor Marshall. Ellex 2RT clinical trials will next commence in Australia, followed by multiple centers internationally over the next 12 months. These trials will provide data necessary to develop a commercial product based on the current prototype 2RT laser systems. The company estimates it will take six months to one year to design and release a product for sale once a decision is made to commercialize Ellex 2RT.

ABOUT AMD

AMD causes central visual loss and is the leading cause of blindness for people over the age of 60. The U.S. National Eye Institute estimates that there are 1.8 million people with AMD in the Unit
'/>"/>

SOURCE Ellex Medical Lasers Limited
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... August 3, 2015 Global ... to reach USD 24.7 billion by 2022, according ... Inc. Growing prevalence of neurological and musculoskeletal disorders ... over the forecast period. The presence of efficient ... advancement in the technologies coupled with implementation of ...
(Date:8/3/2015)... RADNOR, Pa. , Aug. 3, 2015 ... of laboratory products, services and solutions, announces the redesign of ... its customers. When visiting the new site, ... site with bold colors and vivid images.  Each country site ... , an A to Z product menu; and , ...
(Date:8/3/2015)... 3, 2015  BioElectronics Corporation (OTC Pink: BIEL), maker ... that Andrew J. Whelan , President will be ... "On Business" at 9am EDT on Wednesday, August 5 ... to: http://tunein.com/radio/Money-Matters-Boston-1120-s27548/ ... acceptance the company,s flagship product, ActiPatch Therapy, is achieving ...
Breaking Medicine Technology:Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 2Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 3Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 4Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 5VWR's New Website Redesign Provides Improved Functionality for Customers 2UpTick News Wire Radio Show Will Interview BioElectronics' CEO Andrew Whelan 2
... Reportlinker.com announces that a new market research report ... Colorectal Cancer - France Drug Forecasts and Treatment ... Colorectal Cancer - France ... SummaryGlobalData, the industry analysis specialist, has ...
... West Booth# 19112 -- In anticipation of SupplySide West ... that it has entered into a strategic agreement with Mantrose-Haeuser ... distribution of its HIDROX® products, used in dietary supplement and ... "We are looking at the market for dietary supplements and ...
Cached Medicine Technology:Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 2Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 3Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 4Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 5Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 6Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 7Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 8Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 9Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 10Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 11Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 12Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 13Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 14Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 15CREAGRI Partners With Mantrose-Haeuser Co., Inc. for the Distribution of Its HIDROX® 2CREAGRI Partners With Mantrose-Haeuser Co., Inc. for the Distribution of Its HIDROX® 3
(Date:8/3/2015)... Angeles, CA (PRWEB) , ... August 03, 2015 , ... According to an opinion ... calories out of person’s diet leads to one pound of weight loss may not be ... caloric reduction that translates to one pound of fat varies – based both on the ...
(Date:8/3/2015)... Princeton, NJ (PRWEB) , ... August 03, 2015 ... ... named a finalist in 2015 MarketingProfs Bright Bulb B2B Awards. , The MarketingProfs ... by and for B2B brands. BESLER Consulting's campaign for the launch of their ...
(Date:8/3/2015)... CA (PRWEB) , ... August 03, 2015 , ... ... Hispanic Health notes that while an overwhelming number of Hispanics believe people ... , The overwhelming 70 percent of participants queried said making diet changes was ...
(Date:8/3/2015)... ... August 03, 2015 , ... Social impact organization’s #HelpOneHelpMany ... 2015 – Since winning a South by Southwest® (SXSW®) Interactive Innovation Award in ... whose mission is to develop technology for the sake of humanity – continues ...
(Date:8/3/2015)... ... ... AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solutions ... Wednesday, August 12, 2015 at 9:45am (ET) at Le Parker Meridien in New York, ... be accessed via the investor relations section of the Company’s website. , About AxoGen, ...
Breaking Medicine News(10 mins):Health News:Article Dispelling Weight Loss Myth Correctly Emphasizes the Complicated and Difficult Nature of Weight Loss, Says Dr. Michael Feiz 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 4Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 2Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 4Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2
... Goal of 40 million doses by end of October won,t ... -- Production delays continue to hamper distribution of the H1N1 ... , The vaccine is growing more slowly in egg-based cultures ... this time, Dr. Thomas R. Frieden, director of the U.S. ...
... heart patients when ARB added to ACE inhibitor therapy, study ... angiotensin receptor blocker (ARB) drug to help control blood pressure ... are taking an ACE inhibitor, a new study finds. , ... therapy seems no better than ACE inhibitor therapy alone and ...
... lower-than-normal levels of a naturally-occurring fat hormone may increase ... the blood which claims thousands of lives each year. ... Hospital and the University of Toronto focused on adiponectin, ... organs. The findings were presented this week at the ...
... new Commonwealth Fund report analyzes the similarities, differences, potential ... five committees of jurisdiction in the United States Congress: ... Committees in the Senate and the U.S. House of ... and Commerce committees. The report, Provisions of Comprehensive ...
... research finds that mother,s drug use affects male offspring,s behavior ... monkeys exposed to cocaine in the womb have poor impulse ... research has found. , The male monkeys continued to have ... risk factor for drug abuse, said the researchers, who added ...
... More than half the people who take antidepressants for depression ... depression has been oversimplified and drugs designed to treat it ... the Northwestern University Feinberg School of Medicine. The medications are ... eye instead of the center. A study from ...
Cached Medicine News:Health News:Swine Flu Vaccine Still in Short Supply 2Health News:Swine Flu Vaccine Still in Short Supply 3Health News:Adding Drug Doesn't Help Control Blood Pressure 2Health News:Canadian scientists link fat hormone to death from potentially deadly blood infection 2Health News:Analysis of Congressional health reform bills highlights similarities, differences, costs 2Health News:Cocaine Use in Pregnancy Linked to Impulsivity in Sons 2Health News:Why antidepressants don't work for so many 2Health News:Why antidepressants don't work for so many 3
Bechert-McPherson tying forceps, angled, 10 mm tying platforms....
Shepard tying forceps, round curved platform 8 mm, 8.5 cm....
Girard curved tying forceps made of titanium has curved shafts with 8 mm tying platforms, width of shafts 0,25 mm, TCI platforms, round handle, diam. 6 mm, overall length 99 mm....
Girard straight tying forceps made of titanium has straight shafts with 6 mm tying platforms, width of shafts 0,25 mm, TCI platforms, round handle, diam. 6 mm, overall length 105 mm....
Medicine Products: